Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 255.23 g/mol |
|---|---|
| Molecular Formula | C9H13N5O4 |
| XLogP3 | -1.7 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 255.09675391 g/mol |
| Monoisotopic Mass | 255.09675391 g/mol |
| Topological Polar Surface Area | 135 A^2 |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 346 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Cytovene |
| PubMed Health | Ganciclovir (Injection) |
| Drug Classes | Antiviral |
| Drug Label | Ganciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV). CYTOVENE-IV is the brand name for ganciclovir sodium for injection.CYTOVENE-IV is available as sterile lyophilized powder in strength of 500 mg per vial for intraveno... |
| Active Ingredient | Ganciclovir sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial |
| Market Status | Prescription |
| Company | Roche Palo |
| 2 of 6 | |
|---|---|
| Drug Name | Ganciclovir |
| PubMed Health | Ganciclovir |
| Drug Classes | Antiviral |
| Drug Label | Ganciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV).Ganciclovir is available as 250 mg and 500 mg capsules. Each capsule contains 250 mg or 500 mg ganciclovir, USP respectively, and inactive ingredients croscarmellose s... |
| Active Ingredient | Ganciclovir sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa; Luitpold |
| 3 of 6 | |
|---|---|
| Drug Name | Zirgan |
| PubMed Health | Ganciclovir |
| Drug Classes | Antiviral |
| Drug Label | ZIRGAN (ganciclovir ophthalmic gel) 0.15% contains a sterile, topical antiviral for ophthalmic use. The chemical name is 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (CAS number 82410-32-0). Ganciclovir is represented by the following structu... |
| Active Ingredient | Ganciclovir |
| Dosage Form | Gel |
| Route | Ophthalmic |
| Strength | 0.15% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
| 4 of 6 | |
|---|---|
| Drug Name | Cytovene |
| PubMed Health | Ganciclovir (Injection) |
| Drug Classes | Antiviral |
| Drug Label | Ganciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV). CYTOVENE-IV is the brand name for ganciclovir sodium for injection.CYTOVENE-IV is available as sterile lyophilized powder in strength of 500 mg per vial for intraveno... |
| Active Ingredient | Ganciclovir sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial |
| Market Status | Prescription |
| Company | Roche Palo |
| 5 of 6 | |
|---|---|
| Drug Name | Ganciclovir |
| PubMed Health | Ganciclovir |
| Drug Classes | Antiviral |
| Drug Label | Ganciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV).Ganciclovir is available as 250 mg and 500 mg capsules. Each capsule contains 250 mg or 500 mg ganciclovir, USP respectively, and inactive ingredients croscarmellose s... |
| Active Ingredient | Ganciclovir sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa; Luitpold |
| 6 of 6 | |
|---|---|
| Drug Name | Zirgan |
| PubMed Health | Ganciclovir |
| Drug Classes | Antiviral |
| Drug Label | ZIRGAN (ganciclovir ophthalmic gel) 0.15% contains a sterile, topical antiviral for ophthalmic use. The chemical name is 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (CAS number 82410-32-0). Ganciclovir is represented by the following structu... |
| Active Ingredient | Ganciclovir |
| Dosage Form | Gel |
| Route | Ophthalmic |
| Strength | 0.15% |
| Market Status | Prescription |
| Company | Bausch And Lomb |
Date of Issue : 2024-04-23
Valid Till : 2027-04-22
Written Confirmation Number : WC-0170
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-30
Pay. Date : 2013-01-08
DMF Number : 15567
Submission : 2001-07-31
Status : Active
Type : II
Registration Number : 222MF10281
Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY
Initial Date of Registration : 2010-12-24
Latest Date of Registration :
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-06-02
Pay. Date : 2015-08-07
DMF Number : 28973
Submission : 2015-04-02
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23721
Submission : 2010-04-16
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2017-03-07
Pay. Date : 2017-02-15
DMF Number : 31402
Submission : 2017-02-18
Status : Active
Type : II
NDC Package Code : 59651-108
Start Marketing Date : 2024-01-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27133
Submission : 2013-05-02
Status : Inactive
Type : II
Certificate Number : R1-CEP 2013-123 - Rev 01
Issue Date : 2019-06-20
Type : Chemical
Substance Number : 1752
Status : Valid

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16043
Submission : 2002-07-08
Status : Inactive
Type : II

Certificate Number : CEP 2024-086 - Rev 00
Issue Date : 2025-09-09
Type : Chemical
Substance Number : 1752
Status : Valid


FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Details:
Stimotimagene Copolymer Plasmid is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sarcoma.
Lead Product(s): Stimotimagene Copolymer Plasmid,Ganciclovir
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2022

Lead Product(s) : Stimotimagene Copolymer Plasmid,Ganciclovir
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Details : Stimotimagene Copolymer Plasmid is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sarcoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 13, 2022

Details:
Gancyclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): Ganciclovir,Foscarnet Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Biotest
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2022

Lead Product(s) : Ganciclovir,Foscarnet Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients De...
Details : Gancyclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Lead Product(s): Human Cytomegalovirus Immune Globulin,Ganciclovir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cytogam
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Kamada
Deal Size: $145.0 million Upfront Cash: $95.0 million
Deal Type: Acquisition November 22, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Human Cytomegalovirus Immune Globulin,Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Product Name : Cytogam
Product Type : Protein
Upfront Cash : $95.0 million
November 22, 2021

Details:
Cytomegalovirus Specific T Lymphocytes is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): Cytomegalovirus Specific T Lymphocytes,Foscarnet Sodium,Ganciclovir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Cell & Gene Therapy
Sponsor: Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 28, 2016

Lead Product(s) : Cytomegalovirus Specific T Lymphocytes,Foscarnet Sodium,Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Deal Size : Inapplicable
Deal Type : Inapplicable
CMV-CTL for the Treatment of CMV Infection After HSCT
Details : Cytomegalovirus Specific T Lymphocytes is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 28, 2016

Details:
Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratitis, Herpetic.
Lead Product(s): Ganciclovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Bausch & Lomb Incorporated
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2015

Lead Product(s) : Ganciclovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratitis, Herpetic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rabbit Anti-Thymocyte Globulin is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Transplantation.
Lead Product(s): Rabbit Anti-Thymocyte Globulin,Everolimus,Tacrolimus,Mycophenolate Mofetil,Prednisone,Ganciclovir,Valganciclovir Hydrochloride
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Rho, Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Everolimus, Tacrolimus, Mycophenolate Mofetil, Prednisone, Ganciclovir
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Rho, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
Details : Rabbit Anti-Thymocyte Globulin is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Transplantation.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 14, 2014

Details:
Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis.
Lead Product(s): Ganciclovir,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 17, 2012

Lead Product(s) : Ganciclovir,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2012

Details:
Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Keratoconjunctivitis.
Lead Product(s): Ganciclovir,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Bausch & Lomb Incorporated
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2012

Lead Product(s) : Ganciclovir,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Keratoconjunctivitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Lung Injury.
Lead Product(s): Ganciclovir,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: National Heart, Lung, and Blood Institute | Genentech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ganciclovir,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Heart, Lung, and Blood Institute | Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Lung Injury.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2011

Details:
CMV-Specific T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): CMV-Specific T Cell,Ganciclovir,Valganciclovir Hydrochloride,Foscarnet Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Leukaemia Lymphoma Research | NHS Blood and Transplant | University of Birmingham
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2010

Lead Product(s) : CMV-Specific T Cell,Ganciclovir,Valganciclovir Hydrochloride,Foscarnet Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Leukaemia Lymphoma Research | NHS Blood and Transplant | University of Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Alternate Donor Study of Pre-Emptive Cellular Therapy
Details : CMV-Specific T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 14, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
16
PharmaCompass offers a list of Ganciclovir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ganciclovir manufacturer or Ganciclovir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ganciclovir manufacturer or Ganciclovir supplier.
A Ganciclovir & D5-dgA immunotoxin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ganciclovir & D5-dgA immunotoxin, including repackagers and relabelers. The FDA regulates Ganciclovir & D5-dgA immunotoxin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ganciclovir & D5-dgA immunotoxin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ganciclovir & D5-dgA immunotoxin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Ganciclovir & D5-dgA immunotoxin supplier is an individual or a company that provides Ganciclovir & D5-dgA immunotoxin active pharmaceutical ingredient (API) or Ganciclovir & D5-dgA immunotoxin finished formulations upon request. The Ganciclovir & D5-dgA immunotoxin suppliers may include Ganciclovir & D5-dgA immunotoxin API manufacturers, exporters, distributors and traders.
click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Ganciclovir & D5-dgA immunotoxin DMF (Drug Master File) is a document detailing the whole manufacturing process of Ganciclovir & D5-dgA immunotoxin active pharmaceutical ingredient (API) in detail. Different forms of Ganciclovir & D5-dgA immunotoxin DMFs exist exist since differing nations have different regulations, such as Ganciclovir & D5-dgA immunotoxin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ganciclovir & D5-dgA immunotoxin DMF submitted to regulatory agencies in the US is known as a USDMF. Ganciclovir & D5-dgA immunotoxin USDMF includes data on Ganciclovir & D5-dgA immunotoxin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ganciclovir & D5-dgA immunotoxin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ganciclovir & D5-dgA immunotoxin Drug Master File in Japan (Ganciclovir & D5-dgA immunotoxin JDMF) empowers Ganciclovir & D5-dgA immunotoxin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ganciclovir & D5-dgA immunotoxin JDMF during the approval evaluation for pharmaceutical products. At the time of Ganciclovir & D5-dgA immunotoxin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with JDMF on PharmaCompass.
A Ganciclovir & D5-dgA immunotoxin CEP of the European Pharmacopoeia monograph is often referred to as a Ganciclovir & D5-dgA immunotoxin Certificate of Suitability (COS). The purpose of a Ganciclovir & D5-dgA immunotoxin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ganciclovir & D5-dgA immunotoxin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ganciclovir & D5-dgA immunotoxin to their clients by showing that a Ganciclovir & D5-dgA immunotoxin CEP has been issued for it. The manufacturer submits a Ganciclovir & D5-dgA immunotoxin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ganciclovir & D5-dgA immunotoxin CEP holder for the record. Additionally, the data presented in the Ganciclovir & D5-dgA immunotoxin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ganciclovir & D5-dgA immunotoxin DMF.
A Ganciclovir & D5-dgA immunotoxin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ganciclovir & D5-dgA immunotoxin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with CEP (COS) on PharmaCompass.
A Ganciclovir & D5-dgA immunotoxin written confirmation (Ganciclovir & D5-dgA immunotoxin WC) is an official document issued by a regulatory agency to a Ganciclovir & D5-dgA immunotoxin manufacturer, verifying that the manufacturing facility of a Ganciclovir & D5-dgA immunotoxin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ganciclovir & D5-dgA immunotoxin APIs or Ganciclovir & D5-dgA immunotoxin finished pharmaceutical products to another nation, regulatory agencies frequently require a Ganciclovir & D5-dgA immunotoxin WC (written confirmation) as part of the regulatory process.
click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ganciclovir & D5-dgA immunotoxin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ganciclovir & D5-dgA immunotoxin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ganciclovir & D5-dgA immunotoxin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ganciclovir & D5-dgA immunotoxin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ganciclovir & D5-dgA immunotoxin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ganciclovir & D5-dgA immunotoxin suppliers with NDC on PharmaCompass.
Ganciclovir & D5-dgA immunotoxin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ganciclovir & D5-dgA immunotoxin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ganciclovir & D5-dgA immunotoxin GMP manufacturer or Ganciclovir & D5-dgA immunotoxin GMP API supplier for your needs.
A Ganciclovir & D5-dgA immunotoxin CoA (Certificate of Analysis) is a formal document that attests to Ganciclovir & D5-dgA immunotoxin's compliance with Ganciclovir & D5-dgA immunotoxin specifications and serves as a tool for batch-level quality control.
Ganciclovir & D5-dgA immunotoxin CoA mostly includes findings from lab analyses of a specific batch. For each Ganciclovir & D5-dgA immunotoxin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ganciclovir & D5-dgA immunotoxin may be tested according to a variety of international standards, such as European Pharmacopoeia (Ganciclovir & D5-dgA immunotoxin EP), Ganciclovir & D5-dgA immunotoxin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ganciclovir & D5-dgA immunotoxin USP).